WebFeb 17, 2024 · Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the … WebNov 28, 2024 · Cyclophosphamide Dosage Medically reviewed by Drugs.com. Last updated on Nov 28, 2024. Applies to the following strengths: 100 mg; 200 mg; 500 mg; 1 …
(PDF) Autoimmune thrombocytopenia: Current treatment options …
WebCyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in a limited number of patients, its high efficacy and ease of administration have led to its widespread use. WebSign up today to receive the latest news and updates from UpToDate. Sign Up top secondary schools in birmingham
Corticosteroids Plus Intravenous Immune Globulin (IVIg) Versus ...
WebSep 22, 2016 · The optimal dose of rituximab for ITP treatment has not been established. We use 375 mg/m 2 once per week × 4 weeks, but lower doses may be effective ( Table 2 ). 20 Rituximab is generally well tolerated. Toxicities include infusion reactions, serum … WebCyclophosphamide slows cell growth as well as suppresses the immune system. Most often used to treat lymphoma or other cancers, it alters T-cells 2, a type of white blood cell, and may be preferentially considered for those ITP patients who have T-cell abnormalities. 3 WebRituximab, cyclophosphamide and dexamethasone (RCD) effectively target lymphocytes and inhibit autoimmune processes. We reviewed 21 patients with CLL treated for AIHA … top secondary grammar schools uk